{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:21Z","timestamp":1791612441134,"version":"4.3.4"},"reference-count":28,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use has increased exponentially as studies show significant benefits in cardiovascular and renal diseases and obesity. Accessibility to the public also increased after compounding pharmacies began direct-to-consumer distribution. Gastrointestinal side effects are common; however, hypersensitivity reactions are rare. Case Presentation: A 50-year-old female with a history of obesity, hypertension, and lisinopril-induced angioedema presented to the Emergency Department with swelling of the lips, tongue, and throat developing four hours after her first injection of compounded semaglutide for weight loss. She was treated with epinephrine, corticosteroids, and antihistamines, but due to progressive airway edema, she required intubation and mechanical ventilation for four days. After extubation, she reported accidentally injecting a ten-fold higher dose (2 mg) of semaglutide than was appropriate for the first dose. The hospitalization was complicated by hypoglycemia requiring dextrose infusion, but was otherwise unremarkable, and she was discharged home on day 7. Based on the temporal onset after semaglutide injection, this presentation was most consistent with GLP-1 RA-induced angioedema. While she also had a history of lisinopril-induced angioedema five years earlier, and had been taking valsartan for hypertension, the remoteness of the lisinopril exposure made this less likely. Conclusions: Semaglutide use may be associated with severe angioedema within hours of administration. Given the overlapping indications and patient populations, angioedema appearing in patients taking both GLP-1 RAs and ACE inhibitors may become increasingly common and present a diagnostic dilemma. Diagnosis of hypersensitivity to GLP-1 RAs can be supported with history and positive skin testing. Clinicians should be aware that inexperienced patients are at the highest risk of dosing errors.<\/jats:p>","DOI":"10.3390\/jcm15103705","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:04:36Z","timestamp":1778601876000},"page":"3705","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angioedema After Accidental Semaglutide Dosing Error: A Case Report"],"prefix":"10.3390","volume":"15","author":[{"given":"Bryan D.","family":"Kraft","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110-1010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4410-0720","authenticated-orcid":false,"given":"Sarah","family":"Matuszak","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: A randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"Food and Drug Administration (2025, May 31). FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products, Available online: https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded?utm_medium=email&utm_source=govdelivery."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2337\/dc23-1911","article-title":"Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study","volume":"47","author":"Anthony","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_8","first-page":"e51460","article-title":"A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide\/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide","volume":"16","author":"Le","year":"2024","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/8755122514539462","article-title":"Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide","volume":"30","author":"Steveling","year":"2014","journal-title":"J. Pharm. Technol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.18176\/jiaci.0521","article-title":"Delayed Hypersensitivity Reaction to Liraglutide: A Case Report","volume":"30","author":"Carvallo","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.anai.2022.08.735","article-title":"The first report of angioedema and anaphylaxis with temporal association to semaglutide","volume":"129","author":"Feinstein","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/jvc2.255","article-title":"Hypersensitivity to glucagon-like peptide-1 receptor agonists: A case of delayed urticaria-like rash to dulaglutide and literature review","volume":"3","author":"Bianchi","year":"2024","journal-title":"JEADV Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary Angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/acem.12341","article-title":"A consensus parameter for the evaluation and management of angioedema in the emergency department","volume":"21","author":"Moellman","year":"2014","journal-title":"Acad. Emerg. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(19)30382-1","article-title":"Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: A pharmacovigilance analysis","volume":"8","author":"Pradhan","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"G23","DOI":"10.1152\/ajpgi.00189.2019","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves","volume":"319","author":"Mayer","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/joim.12867","article-title":"Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors\u2014A nationwide registry-based cohort study","volume":"285","author":"Rasmussen","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.waojou.2023.100809","article-title":"Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers","volume":"16","author":"Douillard","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.26502\/aimr.0189","article-title":"Semaglutide: Double-edged Sword with Risks and Benefits","volume":"8","author":"Pillarisetti","year":"2025","journal-title":"Arch. Intern. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): A double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: A real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_24","unstructured":"Novo Nordisk (2020). OZEMPIC (Semaglutide); Package Insert, Novo Nordisk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14740338.2024.2430306","article-title":"Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: A population-based study","volume":"25","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/14740338.2025.2499670","article-title":"Safety analysis of compounded GLP-1 receptor agonists: A pharmacovigilance study using the FDA adverse event reporting system","volume":"25","author":"McCall","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_27","unstructured":"Food and Drug Administration (2025, June 10). Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy), Available online: https:\/\/www.fda.gov\/media\/185526\/download?attachment."},{"key":"ref_28","unstructured":"Hoover, J. (2025). The FDA Removes Semaglutide from the Drug Shortage List, Birmingham Medical News."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3705\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:27:13Z","timestamp":1778603233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103705"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103705","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}